Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Talking Healthtech

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by FDA for expanded melanoma use

More than 97,000 cases of melanoma are expected to be diagnosed in the US in 2023

- PMLiVE

FDA establishes new advisory committee to provide expertise on digital health

The committee will consist of individuals with technical and scientific expertise from diverse disciplines and backgrounds

- PMLiVE

Almirall and EpimAb Biotherapeutics enter $210m bispecific antibody partnership

The agreement gives Almirall access to EpimAb’s FIT-Ig drug discovery platform

- PMLiVE

BMS shares positive three-year results for Sotyktu in plaque psoriasis

Up to 100 million people worldwide are affected by some form of the immune-mediated disease

- PMLiVE

Sanofi partners with AI specialist BioMap in deal worth more than $1bn

The strategic collaboration is aimed at accelerating drug discovery for biotherapeutics

EU flag

New EU study highlights psychological challenges of living with skin diseases

Almost half of European adults declared at least one dermatological disease

- PMLiVE

Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn

The transaction would mark a significant boost to the US drugmaker’s oncology portfolio

- PMLiVE

Disseminating Outcomes and Impact in Berlin

The Medscape Education Global team is looking forward to a busy time in Berlin at the EADV Congress 2023. During the congress, Medscape will be presenting five posters examining the...

Medscape Education Global

- PMLiVE

ScreenPoint Medical to showcase AI software at European scientific meeting

Trial results show that the software boosts breast cancer detection by 20%

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

- PMLiVE

DeepMind’s AI tool classifies effects of mutations in genetic diseases

The Google unit's AlphaMissense tool has classified the effects of 71 million ‘missense’ mutations

- PMLiVE

Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia

The deals aim to accelerate drug development in oncology, neurology and immunology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links